March 2013 Issue of MMM
March 2013 Issue
With the advent of expansive data, risk management has evolved to include assessment of the risk of not doing things.
You have fewer than six weeks to enter the MM&M Awards. No problem. Give yourself the best chance of success by following our checklist of ...
Meeting pharma's value-based reimbursement challenge: Marc Iskowitz looks at how companies, driven by payer and provider pressure, are leveraging Big Data across the product lifecycle
Pharma's turn to specialty drugs hasn't been good for print. Ad pages in medical/surgical journals fell steeply in 2012, despite the pickup in FDA approvals. ...
Patent clocks are ticking on branded biologics worth billions. As time runs out, it's not clear when look-alikes will arrive in the US or be ...
The industry turned out in droves to honor three luminaries and the 2013 'Future Famers' at the Medical Advertising Hall of Fame induction dinner on ...
Mike Cunnion, CEO, Remedy Health Media
The prevalence of diabetes and obesity is still high, despite piecemeal attempts at treating them. Among drug makers' latest efforts: pills that address both at ...
Marketing teams are not going to succeed in the future without a real understanding of the real world
The news from the CDC that this year's flu vaccine appears to be less than 60 percent effective at preventing severe flu symptoms, and only ...
With the dust beginning to settle on CMS's final rule for the Sunshine provisions of Obamacare, winner and losers are starting to emerge from the ...
Drug maker Santarus is bringing on 85 reps ahead of the launch of its ulcerative colitis drug Uceris.
Physician trust in pharmaceutical brands is driven by an emotional connection as well as functional attributes and perceptions of the manufacturer, said Harris Interactive
News on FDA, Pfizer and PhRMA
Med Ed Report
The final ruling regarding collecting data on industry payments to physicians from HHS's Centers for Medicare & Medicaid Services has several elements that are significant ...
The ACCME clarified its rule on management and reporting of payments to reserve space for satellite symposia.
An MMIS survey of 1,000 physicians showed that over half didn't know that the Sunshine Act requires companies to report on expenditures annually
News on the Royal College of Physicians, Pri-Med, Georgetown University Medical Center and ReachMD
A piece in open-access journal PLOS that highlights problems with the current state of published clinical trial data.
News on Current Psychiatry, BIoMed Central, Elsevier and Wiley
How can agencies establish brand identities for specialty drugs without looking too self-promotional?
Remedy Health Media is partnering with the University of California-Berkeley on BerkeleyWellness.com, which will deliver wellness information to consumers
AccentHealth is beefing up the digital side of its business with its acquisition of MediVista Media's Everwell TV network.
News on Everyday Health, Google, WebMD and HHS
After several years of quiet among prescription sleep aids, Purdue Pharma has issued a wake-up call to the category with ads featuring an anthropomorphic lightbulb.
This winter's Flu season reached "epidemic" proportions in many communities. This could be seen as great news for hand sanitizers, and for Genentech's Tamiflu antiviral ...
Arnold Worldwide has tapped Martin Laiks to lead the shop's Sanofi business.
"The marketing research community should be very satisfied with the additional guidance on the Sunshine Act from CMS," said the PMRG's government affairs committee chair
GSK Consumer Health Care is the newest member of a research organization that conducts experiments into how shoppers think and behave.
Draftfcb Healthcare is filling out its global footprint through an alliance with Argon Network, a coalition of 22 indie agencies in Europe, Asia, the Middle ...
inVentiv is merging four of its digital agencies into two full-service shops: GSW, Fueled by Blue Diesel and Ignite + Palio.
News on Ogilvy CommonHealth Worldwide, McCann and Havas Life
While we all like the sun, life under the final rules for the "Sunshine Act" provisions of the Affordable Care Act is going to be ...
FDA is exploring an alternative drug-approval pathway for drugs intended to address unmet medical needs by "limited use" approvals.
The Alabama Supreme Court ruled that a man who claims he was injured by a generic version of Pfizer's Reglan can sue the innovator company.
Marketing no longer trashes men, it celebrates them—time for healthcare to do the same
Marketing and sales executives write off government sales due to misconceptions—and truths
Taking a look at who different pharmacies are, or maybe who they want us to think they are, today
Frank Lavelle, CEO, Symphony Health Solutions
At Work With
Matt Hallett, VP of Product, Appature
Manufacturer, agency, programming and research promotions and hires
A scientific approach to marketing could yield efficiencies at every stage
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.